Descripción de la empresa
Fate Therapeutics, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to developing programmed cellular immunotherapies designed to treat cancer and immune disorders both within the United States and in international markets. The company functions within the Healthcare sector, specifically inside the Biotechnology industry, positioning itself as a specialized developer of chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates rather than a traditional small-molecule drug manufacturer. The organization currently maintains a market capitalization of $133.70M, generates annual revenue of $6.65M, and employs a workforce of 161 individuals to execute its research and development objectives. These financial scales indicate that Fate Therapeutics is a micro-cap entity with limited revenue generation relative to its valuation, reflecting the typical capital-intensive nature of biotechnology firms that are still in the clinical development phase and have not yet achieved commercial profitability or widespread market penetration.
Salud financiera
The company reported a trailing twelve-month revenue of $6.65M, yet recorded a significant net income loss of $-136,315,000 and an EBITDA of $-133,703,000, revealing a cost structure where operating expenses heavily outweigh revenue contributions. The gap between the modest revenue figure and the substantial net loss demonstrates that the company is burning cash rapidly to fund clinical trials and operational overhead before generating commercial sales. Free cash flow stands at $-51,558,500, indicating a negative financial flexibility situation where the company must rely on external capital sources to fund its ongoing operations and development pipeline. All three margin metrics reflect this unprofitable stage: the gross margin is 0.0%, the operating margin is -2455.9%, and the profit margin is 0.0%, all figures suggesting that current revenue does not cover the direct costs of production or the broader operational expenses. The balance sheet shows $203.66M in cash assets against $77.85M in debt, resulting in a debt-to-equity ratio of 37.58, which implies a leveraged position despite the substantial cash cushion available. However, the current ratio of 5.79 indicates a very strong short-term liquidity position, suggesting the company can easily meet its immediate obligations with its liquid assets. Return on Equity is -51.8% and Return on Assets is -24.1%, metrics that reveal that management has not yet been effective in generating positive returns on shareholder equity or total assets due to the lack of commercial revenue.
Evaluación de valoración
Valuation multiples for Fate Therapeutics present a complex picture: the P/E Ratio (TTM) is N/A due to losses, while the Forward P/E is -1.10, implying that expected earnings are still negative and the market is pricing the stock based on future potential rather than current profitability. The Price to Book ratio is 0.64, indicating that the market values the company at less than its book value, which often occurs with biotech firms facing high uncertainty regarding the commercial success of their product candidates. Alternative valuation metrics such as the Price to Sales ratio of 20.12 and an EV/EBITDA of -0.06 suggest that investors are willing to pay a significant premium relative to sales, driven by the potential value of the pipeline rather than current earnings power. The stock's trading range over the last year spans from a 52-week low of $0.83 to a 52-week high of $1.94, providing a reference point for price volatility within the biotechnology sector. The Beta of 2.24 indicates that the stock price is highly volatile, moving more than twice as much as the broader market in either direction, which amplifies risk for price-sensitive investors.
Growth & Income
Revenue growth year-over-year is -26.4%, while earnings growth is N/A, indicating that the company is experiencing a contraction in revenue that is not offset by any growth in profitability since it remains unprofitable. The company does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning that instead of distributing income to shareholders, the organization retains all earnings to fund its research and development efforts. This reinvestment strategy is standard for clinical-stage biopharmaceuticals that require significant capital to advance their chimeric antigen receptor (CAR)-targeted product candidates through clinical trials before reaching commercialization. Consequently, the overall growth and income profile is characterized by negative revenue momentum and a complete absence of income generation, relying entirely on the successful progression of its therapeutic pipeline to eventually drive future growth.